Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Total Current Liabilities of $89.5 million for Q1 2026, up 34.31% year-over-year from $66.6 million in Q1 2025, and down 9.82% quarter-over-quarter from $99.2 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $89.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 34.31% year-over-year to $89.5 million; the TTM figure through Mar 2026 stood at $89.5 million (up 34.31% YoY), while the FY2025 annual figure was $99.2 million, up 56.77% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $89.5 million, down from $99.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $99.2 million in Q4 2025, with the low at $44.0 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $59.2 million (2022), against an average of $64.9 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities dropped 23.14% in 2023, then soared 73.81% in 2025.
- Rigel Pharmaceuticals' Total Current Liabilities stood at $65.2 million in 2022, then dropped by 18.32% to $53.3 million in 2023, then climbed by 18.83% to $63.3 million in 2024, then soared by 56.77% to $99.2 million in 2025, then retreated by 9.82% to $89.5 million in 2026.
- Business Quant data shows RIGL's Total Current Liabilities at $89.5 million in Q1 2026, $99.2 million in Q4 2025, and $94.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 95.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.59 Mn |
| Mar 31, 2026 | 89.49 Mn |
| Dec 31, 2025 | 99.24 Mn |
| Sep 30, 2025 | 94.40 Mn |
| Jun 30, 2025 | 86.64 Mn |
| Mar 31, 2025 | 66.63 Mn |
| Dec 31, 2024 | 63.30 Mn |
| Sep 30, 2024 | 54.31 Mn |
| Jun 30, 2024 | 58.65 Mn |
| Mar 31, 2024 | 73.20 Mn |
| Dec 31, 2023 | 53.27 Mn |
| Sep 30, 2023 | 48.27 Mn |
| Jun 30, 2023 | 44.02 Mn |
| Mar 31, 2023 | 45.52 Mn |
| Dec 31, 2022 | 65.21 Mn |
| Sep 30, 2022 | 47.27 Mn |
| Jun 30, 2022 | 54.96 Mn |
| Mar 31, 2022 | 59.23 Mn |
| Dec 31, 2021 | 63.55 Mn |
| Sep 30, 2021 | 59.28 Mn |